GW-788388
GW-788388 is a small molecule inhibitor that has been studied for its potential therapeutic effects in various fibrotic diseases. It primarily functions as an inhibitor of the transforming growth factor beta (TGF-β) receptor, which plays a crucial role in the pathogenesis of fibrosis.
Mechanism of Action[edit | edit source]
GW-788388 acts by selectively inhibiting the activity of the TGF-β type I receptor kinase. TGF-β is a cytokine that is involved in the regulation of cell growth, differentiation, and immune responses. It is also a key mediator in the development of fibrosis, a pathological process characterized by excessive deposition of extracellular matrix components such as collagen.
By inhibiting the TGF-β receptor, GW-788388 can potentially reduce the signaling pathways that lead to fibrosis. This makes it a promising candidate for the treatment of diseases where fibrosis is a major component, such as idiopathic pulmonary fibrosis, liver cirrhosis, and chronic kidney disease.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of GW-788388 includes its absorption, distribution, metabolism, and excretion characteristics. Studies have shown that GW-788388 is orally bioavailable and can reach therapeutic concentrations in target tissues. It is metabolized primarily in the liver and excreted via the kidneys.
Clinical Research[edit | edit source]
Preclinical studies have demonstrated the efficacy of GW-788388 in animal models of fibrosis. These studies have shown that treatment with GW-788388 can lead to a reduction in fibrotic tissue and improvement in organ function. However, as of the latest updates, GW-788388 is still undergoing clinical trials to evaluate its safety and efficacy in humans.
Potential Applications[edit | edit source]
GW-788388 has potential applications in the treatment of several fibrotic conditions, including:
Safety and Side Effects[edit | edit source]
The safety profile of GW-788388 is still being evaluated in clinical trials. Potential side effects may include gastrointestinal disturbances, liver enzyme alterations, and other effects related to its mechanism of action.
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
